David Westenberg
Stock Analyst at Piper Sandler
(4.48)
# 395
Out of 5,178 analysts
184
Total ratings
53.57%
Success rate
20.34%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WGS GeneDx Holdings | Maintains: Overweight | $160 → $130 | $61.35 | +111.90% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $130 | $88.10 | +47.56% | 11 | Feb 24, 2026 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $13 | $7.76 | +67.53% | 11 | Feb 24, 2026 | |
| LH Labcorp Holdings | Maintains: Neutral | $270 → $300 | $268.38 | +11.78% | 5 | Feb 24, 2026 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $775 → $750 | $573.29 | +30.82% | 12 | Feb 9, 2026 | |
| ILMN Illumina | Maintains: Overweight | $195 → $170 | $124.40 | +36.66% | 17 | Feb 9, 2026 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $24 → $30 | $24.58 | +22.05% | 11 | Jan 22, 2026 | |
| ZTS Zoetis | Downgrades: Neutral | $190 → $135 | $116.63 | +15.75% | 16 | Jan 22, 2026 | |
| NEOG Neogen | Reiterates: Neutral | $6.5 → $10 | $9.15 | +9.29% | 14 | Jan 12, 2026 | |
| BLLN BillionToOne | Initiates: Overweight | $150 | $71.44 | +109.97% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $19 | $20.43 | -7.00% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $80 | $45.53 | +75.71% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $2 | $1.35 | +48.15% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $230 | $196.15 | +17.26% | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $30 | $16.37 | +83.26% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7.5 | $4.58 | +63.76% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $200 | $198.15 | +0.93% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $13.96 | +43.27% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $15.60 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $26.04 | - | 1 | Nov 21, 2017 |
GeneDx Holdings
Feb 24, 2026
Maintains: Overweight
Price Target: $160 → $130
Current: $61.35
Upside: +111.90%
Guardant Health
Feb 24, 2026
Maintains: Overweight
Price Target: $120 → $130
Current: $88.10
Upside: +47.56%
NeoGenomics
Feb 24, 2026
Maintains: Overweight
Price Target: $12 → $13
Current: $7.76
Upside: +67.53%
Labcorp Holdings
Feb 24, 2026
Maintains: Neutral
Price Target: $270 → $300
Current: $268.38
Upside: +11.78%
IDEXX Laboratories
Feb 9, 2026
Maintains: Neutral
Price Target: $775 → $750
Current: $573.29
Upside: +30.82%
Illumina
Feb 9, 2026
Maintains: Overweight
Price Target: $195 → $170
Current: $124.40
Upside: +36.66%
Elanco Animal Health
Jan 22, 2026
Upgrades: Overweight
Price Target: $24 → $30
Current: $24.58
Upside: +22.05%
Zoetis
Jan 22, 2026
Downgrades: Neutral
Price Target: $190 → $135
Current: $116.63
Upside: +15.75%
Neogen
Jan 12, 2026
Reiterates: Neutral
Price Target: $6.5 → $10
Current: $9.15
Upside: +9.29%
BillionToOne
Dec 1, 2025
Initiates: Overweight
Price Target: $150
Current: $71.44
Upside: +109.97%
Nov 11, 2025
Maintains: Neutral
Price Target: $15 → $19
Current: $20.43
Upside: -7.00%
Nov 11, 2025
Maintains: Neutral
Price Target: $105 → $80
Current: $45.53
Upside: +75.71%
Nov 11, 2025
Maintains: Neutral
Price Target: $1.5 → $2
Current: $1.35
Upside: +48.15%
Nov 11, 2025
Maintains: Overweight
Price Target: $220 → $230
Current: $196.15
Upside: +17.26%
Nov 11, 2025
Maintains: Neutral
Price Target: $21 → $30
Current: $16.37
Upside: +83.26%
Nov 11, 2025
Maintains: Overweight
Price Target: $8 → $7.5
Current: $4.58
Upside: +63.76%
Oct 27, 2025
Maintains: Neutral
Price Target: $190 → $200
Current: $198.15
Upside: +0.93%
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $13.96
Upside: +43.27%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $15.60
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $26.04
Upside: -